ʻSparkʼ, a new public-private project created to develop a drug against schizophrenia cognitive impairment

The drug candidate is IPR019; it belongs to a family of compounds named 'third generation' developed and patented by Iproteos, coordinator of the project.
The drug candidate is IPR019; it belongs to a family of compounds named 'third generation' developed and patented by Iproteos, coordinator of the project.
Research
(29/01/2015)

To advance the development of a new neuroprotective drug for the treatment of the cognitive impairment associated with schizophrenia and other mental disorders is the main goal of a project fostered by a public-private consortium led by the biotech Iproteos, an spin-off of the University of Barcelona and the Institute for Research in Biomedicine (IRB Barcelona), headquartered at the Barcelona Science Park (PCB). The project has just received a 500,000 euro grant from the Ministry of Economy and Finance, and it comprises the biopharmaceutical company Ascil-Biopharma, the Institute for Research in Biomedicine (IRB Barcelona), the Centre for Genomic Regulation (CRG) and the University of the Basque Country (UPV/EHU).

The drug candidate is IPR019; it belongs to a family of compounds named 'third generation' developed and patented by Iproteos, coordinator of the project.
The drug candidate is IPR019; it belongs to a family of compounds named 'third generation' developed and patented by Iproteos, coordinator of the project.
Research
29/01/2015

To advance the development of a new neuroprotective drug for the treatment of the cognitive impairment associated with schizophrenia and other mental disorders is the main goal of a project fostered by a public-private consortium led by the biotech Iproteos, an spin-off of the University of Barcelona and the Institute for Research in Biomedicine (IRB Barcelona), headquartered at the Barcelona Science Park (PCB). The project has just received a 500,000 euro grant from the Ministry of Economy and Finance, and it comprises the biopharmaceutical company Ascil-Biopharma, the Institute for Research in Biomedicine (IRB Barcelona), the Centre for Genomic Regulation (CRG) and the University of the Basque Country (UPV/EHU).

The drug candidate is IPR019; it belongs to a family of compounds named 'third generation' developed and patented by Iproteos, coordinator of the project. Iproteos —the biotech created in 2011 by Ernest Giralt, professor in the Department of Organic Chemistry of UB, and Teresa Tarragó, researcher in IRB Barcelona— will assess the metabolism and toxicity of candidate compounds and their activity once administered orally and subcutaneously in animal models.

Further information